RWE4Decisions REAL WORLD EVIDENCE
PUBLIC WEBINAR SERIES

Supporting HTA/Payer decision-making: Health data initiatives in Germany

Wednesday, 21 September 2022 | 15.00 – 16.30 CET

SPEAKER BIOGRAPHIES

Karen Facey (co-moderator)
Evidence Based Health Policy Consultant to RWE4Decisions Secretariat

Dr. Karen Facey worked as a senior statistician in the pharmaceutical sector and UK medicines regulation, before becoming the founding Chief Executive of the first national HTA agency in Scotland. Since 2003, Dr Facey has been an independent consultant on health policy, HTA and patient involvement. She has served as Non-Executive Director on Scottish health boards and led research at the University of Edinburgh on appraisal of rare disease treatments in the IMPACT HTA project. She is passionate about holistic HTA to determine value and use of health service data to improve patient care. Dr Facey has facilitated the development of the RWE4Decisions multi-stakeholder initiative and is the lead author of the paper on 'Real-World Evidence to Support Payer/HTA Decisions about Highly Innovative Technologies in the EU – Actions for Stakeholders', commissioned by the Belgian payer INAMI-RIZIV.

Diane Kleinermans (co-moderator)
President of the Commission of Drugs Reimbursement, National Institute of Health and Disability Insurance (INAMI-RIZIV), Belgium

Diane Kleinermans has been appointed President of the Commission of Drugs Reimbursement at the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV), after having served as an internal expert to the Commission since 2008, being amongst others in charge of orphan drugs assessments. From 2015 to 2020, she was advisor to the Belgian Minister of Public Health and Social Affairs Maggie De Block, focusing on drug policy, clinical trials and the BeNeLuxA/ IHSI initiatives. Diane started her career as a GP in Brussels. Until 2007, she worked with the pharmaceutical industry in R&D in Belgium and abroad; she worked amongst other for Pfizer, Novartis Opthalmics and GSK. Diane has been closely involved in the multi-stakeholder roundtables considering the use of RWE to ensure short term affordability, long-term sustainability and optimal patient care.

RWE4Decisions REAL WORLD EVIDENCE
PUBLIC WEBINAR SERIES

Dr. Antje Behring

Head of Pharmaceuticals Department, German Federal Joint Committee (G-BA)

Pharmacist by training, Dr. Antje Behring currently serves as Head of the Pharmaceuticals Department at the German Federal Joint Committee (Gemeinsamen Bundesausschusses/G-BA). Since she joined the G-BA, Dr. Behring has been leading the early benefit assessment team and is also involved in the additional benefit assessment procedure for new pharmaceutical products. She is also the Chair of the Committee for scientific consistency and quality (CSCQ) for Joint Scientific Consultation (JSC) in EUnetHTA21.

Before joining the G-BA, Dr. Behring was a consulting pharmacist for a German health insurance company. Prior to her involvement in the pharmaceutical area, she worked as a physiotherapist both in the outpatient and inpatient sector. Dr. Behring graduated with a PharmD and PhD in pharmaceutical science from the University of Munich.

Dr. Martin Danner

Managing Director, Federal Association of Self-Help Organisations for people with disabilities and chronic diseases and their relatives (BAG Selbsthilfe)

Dr. Martin Danner is a lawyer by profession and is the Managing Director at the Federal Association of Self-Help Organisations for people with disabilities and chronic diseases and their relatives (BAG Selbsthilfe). Next to taking the role of patients' representative spokesman at the Federal Joint Committee (G-BA), Dr. Danner is also active on the Scientific Advisory Board of the Medical Centre for Quality in Medicine (ÄZQ). He is also a member of various health policy committees, such as the IQWIG Board of Trustees, the Advisory Board for the Participation of Disabled People at the Federal Ministry of Labour and Social Affairs. Before joining BAG Selbsthilfe, Dr. Danner carried his legal studies in Heidelberg and practiced as a lawyer for several years, specialising in health law.

Dr. Barthold Deiters

Head of Pharmaceuticals, Society for Efficiency and Quality in Health Insurance Companies (GWQ ServicePlus AG)

Dr. Barthold Deiters is Head of Pharmaceuticals at the Society for Efficiency and Quality in Health Insurance Companies (GWQ ServicePlus AG) – a service provider for health insurers. In his current role, Dr. Deiters is focusing on the assessment of effectiveness in everyday care medical interventions. Prior to GWQ Service Plus, Dr. Deiters served as pharmacist at the BKK Bundesverband, an organisation representing the interests of health insurance companies in Germany. He also held the position of Head of Pharmaceutical Contracts at the Vereinigte IKK, one of the largest health insurance funds in Germany. Dr. Dieters studied pharmacy in Münster and completed his doctorate at the Institute for Physiological Chemistry and Pathobiochemistry at Münster University Hospital.

RWE4Decisions
REAL WORLD EVIDENCE
PUBLIC WEBINAR SERIES

Dr. Alexander Natz

Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Dr. Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), a position he holds since 2010. He also works as a lawyer for the law firm Novacos and advises pharmaceutical and biotech companies in regulatory and pricing & reimbursement decisions from an EU and German law perspective. From 2008 to 2013, he was the head of the Brussels office of the German Pharmaceutical Industry Association (BPI). Dr. Natz also worked in the field of competition law with the European Commission and in the pharmaceutical industry. He was a research assistant at Duke University (USA) where he dealt with international pharmaceutical law.